13 April 2021
Avacta Group plc
("Avacta" or "the Group")
Notice of Results and Investor Presentation
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, will announce its financial results for the 12 months ended 31 December 2020 on Thursday, 22 April 2021.
Analyst briefing
A sell-side analyst briefing given by Alastair Smith, Chief Executive Officer; Tony Gardiner, Chief Financial Officer; and Neil Bell, Chief Development Officer, will be held by webcast presentation, followed by a Q&A session, at 9.30am BST on Thursday, 22 April 2021.
Pre-registration is required for attendance to the call. To confirm attendance, please email Avacta@fticonsulting.com and you will be sent the link to join.
The presentation will be posted on the Company's website at the following address:
https://avacta.com/investors/documents-presentations
Investor webinar
An investor webinar presentation by Alastair Smith, Chief Executive Officer; Tony Gardiner, Chief Financial Officer; and Neil Bell, Chief Development Officer, will take place at 11:00am BST on Thursday, 22 April 2021.
The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and then click "Add to meet" Avacta Group via the following link to join the webinar:
https://www.investormeetcompany.com/avacta-group-plc/register-investor
Investors who already follow Avacta Group plc on the Investor Meet Company platform will automatically be invited.
- Ends -
For further information from Avacta Group plc, please contact:
| Avacta Group plc | Tel: +44 (0) 844 414 0452 |
| Alastair Smith, Chief Executive Officer | |
| Tony Gardiner, Chief Financial Officer | |
| | |
| finnCap Ltd (Nominated Adviser and Joint Broker) | Tel: +44 (0) 207 220 0500 |
| Geoff Nash / Giles Rolls - Corporate Finance Tim Redfern - ECM | |
| | |
| Stifel Nicolaus Europe Limited (Joint Broker) | Tel: +44 (0) 207 710 7600 |
| Nicholas Moore / Nick Adams / Fred Walsh / Ben Maddison | |
| | |
| FTI Consulting (Financial Media and IR) | Tel: +44 (0) 203 727 1000 |
| Simon Conway / Stephanie Cuthbert | |
| | |
| Zyme Communications (Trade and Regional Media) | Tel: +44 (0) 7787 502 947 |
| Katie Odgaard |
About Avacta Group plc - https://www.avacta.com
Avacta Group is developing diagnostics and innovative cancer therapies based on its proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.
Avacta's pre|CISION™ targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.
The Group comprises two divisions: The therapeutics development activities are based in Cambridge, UK and the Group is generating near-term revenues from Affimer reagents for diagnostics, bioprocessing and research, through a separate diagnostics business unit based in Wetherby, UK.
Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Group is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test and an AffiDX® BAMS™ SARS-CoV-2 Assay in partnership with Adeptrix Inc.
Avacta's Therapeutics Division is addressing a critical gap in current cancer treatment - the lack of a durable response to current immunotherapies experienced by most patients. By combining its two proprietary platforms the Group is building a wholly owned pipeline of novel cancer therapies deigned to be effective for all cancer patients. In 2021 Avacta will commence a phase 1 first-in-human, open label, dose-escalation and expansion study of AVA6000 Pro-doxorubicin, the Group's lead pre|CISION™ prodrug, in patients with locally advanced or metastatic selected solid tumours.
Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTX,Inc. (formerly Moderna Therapeutics Inc.), a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators, a partnership with ADC Therapeutics to develop Affimer-drug conjugates and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION™ platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
